| Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. F Diurno, FG Numis, G Porta, F Cirillo, S Maddaluno, A Ragozzino, ... European Review for Medical & Pharmacological Sciences 24 (7), 2020 | 421 | 2020 |
| Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients A Ottaiano, R Franco, A Aiello Talamanca, G Liguori, F Tatangelo, ... Clinical cancer research 12 (9), 2795-2803, 2006 | 252 | 2006 |
| Microbiota effects on cancer: from risks to therapies D Rea, G Coppola, G Palma, A Barbieri, A Luciano, P Del Prete, ... Oncotarget 9 (25), 17915, 2018 | 235 | 2018 |
| Epithelial-mesenchymal transition in prostate cancer: an overview M Montanari, S Rossetti, C Cavaliere, C D'Aniello, MG Malzone, ... Oncotarget 8 (21), 35376, 2017 | 214 | 2017 |
| Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive … KN Chi, A Protheroe, A Rodríguez-Antolín, G Facchini, H Suttman, ... The Lancet Oncology 19 (2), 194-206, 2018 | 203 | 2018 |
| Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey M Berretta, C Della Pepa, P Tralongo, A Fulvi, F Martellotta, A Lleshi, ... Oncotarget 8 (15), 24401, 2016 | 201 | 2016 |
| Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone C Lolli, O Caffo, E Scarpi, M Aieta, V Conteduca, F Maines, E Bianchi, ... Frontiers in pharmacology 7, 376, 2016 | 187 | 2016 |
| Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study AO Siefker-Radtke, A Necchi, SH Park, J García-Donas, RA Huddart, ... The lancet oncology 23 (2), 248-258, 2022 | 174 | 2022 |
| Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up of a large series S Del Prete, M Caraglia, D Russo, G Vitale, G Giuberti, M Marra, ... Thyroid 12 (9), 815-821, 2002 | 172 | 2002 |
| Micrornas in prostate cancer: an overview D Vanacore, M Boccellino, S Rossetti, C Cavaliere, C D'Aniello, ... Oncotarget 8 (30), 50240, 2017 | 162 | 2017 |
| Ovarian cancer standard of care: are there real alternatives? C Della Pepa, G Tonini, C Pisano, M Di Napoli, SC Cecere, R Tambaro, ... Chinese journal of cancer 34 (1), 17-27, 2015 | 141 | 2015 |
| Toll-like receptors and COVID-19: a two-faced story with an exciting ending L Onofrio, M Caraglia, G Facchini, V Margherita, SD Placido, C Buonerba Future science OA 6 (8), FSO605, 2020 | 136 | 2020 |
| Extragonadal germ cell tumors: not just a matter of location. A review about clinical, molecular and pathological features A Ronchi, I Cozzolino, M Montella, I Panarese, F Zito Marino, S Rossetti, ... Cancer medicine 8 (16), 6832-6840, 2019 | 134 | 2019 |
| Chemotherapy in epithelial ovarian cancer S Pignata, L Cannella, D Leopardo, C Pisano, GS Bruni, G Facchini Cancer letters 303 (2), 73-83, 2011 | 127 | 2011 |
| First-line treatment of advanced ovarian cancer: current research and perspectives C Marchetti, C Pisano, G Facchini, GS Bruni, FP Magazzino, S Losito, ... Expert review of anticancer therapy 10 (1), 47-60, 2010 | 122 | 2010 |
| Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer C D'alterio, C Consales, M Polimeno, R Franco, L Cindolo, L Portella, ... Current cancer drug targets 10 (7), 772-781, 2010 | 109 | 2010 |
| Resveratrol in cancer patients: from bench to bedside M Berretta, A Bignucolo, R Di Francia, F Comello, G Facchini, ... International journal of molecular sciences 21 (8), 2945, 2020 | 107 | 2020 |
| Multiple effects of ascorbic acid against chronic diseases: Updated evidence from preclinical and clinical studies M Berretta, V Quagliariello, N Maurea, R Di Francia, S Sharifi, G Facchini, ... Antioxidants 9 (12), 1182, 2020 | 103 | 2020 |
| Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO) G Francolini, AG Allegra, B Detti, V Di Cataldo, S Caini, A Bruni, ... Journal of Clinical Oncology 41 (36), 5561-5568, 2023 | 102 | 2023 |
| Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment … O Caffo, U De Giorgi, L Fratino, D Alesini, V Zagonel, G Facchini, ... European urology 68 (1), 147-153, 2015 | 102 | 2015 |
Michele CaragliaProfessore Ordinario di Biochimica, Università della Campania "L. Vanvitelli", Dipartimento diVerified email at unicampania.it
